San Diego, California, United States

Time filter

Source Type

PubMed | Allergy & Asthma Medical Group and Research Center
Type: Clinical Trial, Phase II | Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | Year: 2012

Acute rhinosinusitis (ARS) is triggered by viral or, uncommonly, bacterial infection, causing inflammatory symptoms for 12 weeks.To investigate effects of mometasone furoate nasal spray (MFNS) vs amoxicillin and placebo on minimal-symptom days.A double-blind, parallel-group, placebo- and active-controlled 15-day study randomly assigned patients 12 years of age or older to MFNS 200 g twice daily, MFNS 200 g once daily, amoxicillin 500 mg 3 times daily, or placebo. Patients had baseline rhinosinusitis major symptom score (MSS; combined rhinorrhea, postnasal drip, congestion, sinus headache, facial pain) of 5 and 12 (maximum: 15) for 7 to 28 days; scores were similar among groups. Minimal-symptom days and minimal-congestion days were defined post hoc by average am/pm MSS 4 and average AM/PM congestion 1.MFNS twice daily (n = 234) showed more minimal-symptom days vs placebo (n = 246) (62.69% vs 50.33%; P < .0001) or amoxicillin (n = 248) (54.35%; P = .0040). The MFNS QD was associated with numerically more minimal-symptom days than amoxicillin or placebo (54.72%; P .8982). MFNS was associated with more minimal-congestion days than placebo (72.97%, 67.73%, and 56.67% for twice daily, once daily, and placebo; P < .0001, each vs placebo) and MFNS BID with more minimal-congestion days than amoxicillin (72.97% vs 64.15%; P = .0007). Median time to first minimal-symptom day sustained until study end was 8.5 days for MFNS BID vs. 11 for placebo (P = .0085).MFNS 200 g twice daily significantly increased minimal-symptom days vs amoxicillin or placebo in patients with ARS. Results of this intranasal corticosteroids (INS) therapy indicate it can improve outcomes and potentially reduce inappropriate antibiotic use.


PubMed | Allergy & Asthma Medical Group and Research Center
Type: Journal Article | Journal: Immunology and allergy clinics of North America | Year: 2016

Allergic rhinitis is a highly prevalent and costly condition. The disease burden suffered by patients includes the morbidity of the nasal symptoms, the impairment of multiple domains of quality of life, and numerous comorbidities. The goal of therapy is long-term good control.

Loading Allergy & Asthma Medical Group and Research Center collaborators
Loading Allergy & Asthma Medical Group and Research Center collaborators